A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

Authors

Christine Chung

Christine H. Chung

Moffitt Cancer Center, Tampa, FL

Christine H. Chung , A. Dimitrios Dimitrios Colevas , Douglas Adkins , Cristina P. Rodriguez , Jong Chul Park , Michael K. Gibson , Barbara Burtness , Faye M. Johnson , Ricklie Ann Julian , Nabil F. Saba , Francis P. Worden , Lara Dunn , Tanguy Y. Seiwert , Robert M. Jotte , Julie E. Bauman , Marya F. Chaney , Steven Margossian , Matteo Levisetti , Sara I. Pai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

Clinical trial information: NCT03978689

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6013)

DOI

10.1200/JCO.2023.41.16_suppl.6013

Abstract #

6013

Poster Bd #

5

Abstract Disclosures

Similar Posters